Announced
Completed
Param Capital completed the acquisition of a majority stake in Intron Lifesciences.
Synopsis
Param Capital, a privately owned investment firm, completed the acquisition of a majority stake in Intron Lifesciences, a manufacturer specializing in probiotics and other biotech products. Financial terms were not disclosed.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Claim DealAll rights reserved. Copyright © 2025 Datasite